BioSciCon,%20Inc.

1
BioSciCon, Inc. Business Opportunity 2006 Web
site www.bioscicon.com
2
BioSciCon, Inc.

• BioSciCon has developed and manufactures
  patented biomarker-based MarkPap technology
  products intended for early detection of cervical
  cancer. This technology is more accurate, less
  costly and less invasive than current Pap test
  technologies.

3
Cervical Cancer is preventable

• Cervical cancer is second to the breast cancer
  cause of women deaths from malignant diseases
  world-wide. Currently, there are 500,000 new
  cases of cervical cancer each year, and about
  250,000 die from this preventable disease in 21st
  Century. However, cervical cancer is preventable
  IF detected on time. Best prevention is regular
  cervical cancer screening. Cytological screening
  (Pap test) remains the best cervical cancer
  prevention.

4
WORLD

• Problem
• At risk 1.7 B
• Protected with Pap 110 M or 6.5
• Developing countries 20 M Pap tests or 1.2

• Other technologies
• Screen treat
• VIA
• HPV
• Vaccination

5
The Problem

• Existing Pap Test Technology
• Costly Increasing insurance costs in US and
  prohibitively expensive in developing countries
• Infrastructure required, with qualified
  professionals (cytotechnologists/pathologists)
• Insufficient Reliability (gt15 false negatives)
• Slow Takes weeks to obtain normal results
• Requires visiting a doctor and it is invasive,
  which leads to fewer women being tested

6
The Solution

• MarkPap Test is the solution
• Less costly Priced gt25 less than Pap test
• MarkPap Self and MarkPap Digital make the
  infrastructure affordable for developing
  countries
• More reliable lt5 false negatives
• Less Invasive MarkPap Self, leading to increased
  use by all women
• Timely Results within hours (MarkPap Digital)
• Better controlled QC/QA with control slides and
  less liability for the laboratory

7
MarkPap Technology

• CAP-PAP Test (US patent, 2000)
• CAP-PAP Kit
• (US patent pending)
• International
• (PCT, 2004)
• Trademark MarkPap
• Know-how

Chemical sensitive biomarker flags abnormal
cells for early detection.
8
MarkPap Images
Abnormal specimen, ASC-H. Three small abnormal
(red) cells among several normal
cells. Screening magnification (left).
Diagnostic magnifications (right). Abnormal
cells cannot be missed.
9
MarkPap Products (first line of products)

• MarkPap Research Kit Assembly of reagents,
  instructions and controls.
• Kit Accessories Cytopreservative solution,
  Control slides.
• MarkPap Test service, assay.
• Available for research only in the US (before
  FDA approval). International sale under local
  regulations.

10
MarkPap Research Kit
11
MarkPap Accessories
12
Products in Development

• MarkPap Self
• MarkPap Digital
• MarkPap Self Digital
• MarkPap Cell Bank

13
MarkPap Self
14
MarkPap Self

• MarkPap Self is an option for women to take the
  sample in the privacy of their home and to send
  it in the laboratory. MarkPap Self is aimed for
  women who live in remote parts and do not have
  access to doctors offices, for those who (because
  of different cultural and religious tradition)
  cannot go to gynecologist, or women who are
  simply not comfortable with pelvic exam and
  prefer to take the sample at home. MarkPap Self
  will dramatically increase the number of women
  who will get preventive testing.

15
MarkPap Digital
16
MarkPap Digital

• MarkPap Digital provides a possibility to
  process the sample in a small laboratory/doctor
  office, capture the red biomarker positive
  (abnormal) cells with a digital camera and
  transmit images via Internet into laboratories
  with qualified reviewers for evaluation. The
  result may be available within hours. The cost of
  the image acquisition system consisting of a
  microscope, digital camera and software is below
  5,000.

17
MarkPap Self Digital

• In practice, MarkPap Self and MarkPap Digital
  allow women to take the sample at home and to
  mail it to the nearby laboratory. In this
  laboratory a low-trained technician or nurse can
  stain the slide using easy-to-use MarkPap Kit.
  The same person examines the slide under the
  microscope and searches for red cells. The
  images of those cells are captured with a digital
  camera and transmitted for evaluation. The result
  may be sent back electronically within hours.
  This is how MarkPap technology can provide
  cytological mass cervical screening worldwide and
  save womens lives.

18
Overall Competitive Advantages

• Novel biomarker of abnormality
• Simple and immediately applicable
• Better accuracy for lower cost
• Better productivity for less liability
• Prospect for self-sampling and
  telecytopathology for mass cervical cancer
  screening worldwide
• Huge societal benefit saving womens lives with
  enormous market and incredible potential for
  profit

19
BioSciCon, Inc.

• BioSciCon is a small business, women owned,
  start-up S-corporation, which has completed the
  RD phase for the first line products, and has
  entered a new development phase for the next line
  of products. The company is now searching for
  commercial funding to bring products to market.
• More about BioSciCon at www.bioscicon.com

20
Management team

• Nenad Markovic, MD. PhD, President
• Olivera Markovic, M.D. PhD, Founding Director
• Executive Secretary
• Clinical and Laboratory Sites Managers
• 20 Ob/Gyn, 4 pathologists and GPs in U.S.
  (MD, DC, CA, NY, FL) and abroad
• Mr. Peter Ricca, Ricca Chemical Company,
  Manufacturer
• MarkPap LLC, the business arm of BioSciCon
  (see next)
• Organizational structure presented at
  www.bioscicon.com

21
MarkPap LLC

• BioSciCon has recently incorporated a new
  business entity, the MarkPap LLC. The LLC has
  initiated an executive search from the pool of
  business professionals who already expressed
  strong interest to become LLC Managing Partners.

22
BioSciCon, Inc. 14905 Forest Landing Circle
Rockville, MD 20850 Tel [phone] Fax
301-610-7662 Web site www.bioscicon.com E-mail
info_at_bioscicon.com